This is a summary of the European public assessment report (EPAR) for Strimvelis. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Strimvelis. For practical information about using Strimvelis, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA\-SCID), for whom no suitable human leukocyte antigen (HLA)\-matched related stem cell donor is available (see section 4\.2 and section 4\.4\).
Therapeutic Area (MeSH)
ATC Code
L03
ATC Item
N/A
Pharmacotherapeutic Group
Immunostimulants
Active Substance (Summary)
INN / Common Names
EMA Name
Strimvelis
Medicine Name
Strimvelis
Aliases
N/ANo risk management plan link.
